FindTrial
Sign In

VY-AADC01

BIOLOGICAL2 trials

Sponsors

Neurocrine Biosciences

Conditions

Basal Ganglia DiseaseBrain DiseasesCentral Nervous System DiseasesIdiopathic Parkinson's DiseaseMovement DisordersNervous System DiseasesNeurodegenerative DiseasesParkinson's Disease

Phase 1

Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease
CompletedNCT01973543
Neurocrine BiosciencesParkinson's Disease
Start: 2013-10-31End: 2020-01-24Updated: 2020-03-03
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
CompletedNCT03065192
Neurocrine BiosciencesBasal Ganglia Disease, Brain Diseases, Central Nervous System Diseases +6
Start: 2017-05-11End: 2021-08-10Updated: 2022-03-21

Related Papers

Parkinson's disease gene therapy: a comparative effectiveness review of completed clinical trials in terms of their possible implementation in treatment
MEDICAL SCIENCE PULSE2023-02-271 citations
Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
2021-10-1448 citations
Magnetic resonance imaging–guided phase 1 trial of putaminal <i>AADC</i> gene therapy for Parkinson's disease
Annals of Neurology2019-02-26154 citations
Lentiviral Vector-Based Gene Therapy in Parkinson Disease
Neurosurgery2014-05-20